Cerebral Venous Sinus ThrombosisCCCNCT03919305
Cerebral Venous Thrombosis Cohort Study in China Mainland
An observational study of Cerebral Venous Sinus Thrombosis and Deep Cerebral Vein Thrombosis, run by Capital Medical University at 1 site in China.
Trial summary
This study was aimed to reveal the clinical features,natural history of the diseases and current therapeutic situations of cerebral venous thrombosis (CVT) in China mainland. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cerebral Venous Sinus Thrombosis, Deep Cerebral Vein Thrombosis, Cortical Vein Thrombosis
- How many people
- 3,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2019to 31 Dec 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis.
Who may be able to join
- Cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis diagnosed by digital subtraction angiography (DSA), magnetic resonance venography (MRV), computed tomography venography (CTV) or high-resolution magnetic resonance imaging (HR-MRI).
Who cannot join
- None of the patient, trustee or immediate family members signed the informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xuanwu Hospital, Capital Medical University
Beijing
Min Li, MD, PhD
About this study
This study was aimed to reveal the clinical features,natural history of the diseases and current therapeutic situations of cerebral venous thrombosis (CVT) in China mainland. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT.
Read the detailed description
cerebral venous thrombosis (CVT) is caused by a clot in the cerebral vein, which resulted in an obstruction of the blood outflow. CVT mainly includes cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis. However, the epidemiological features of CVT in China mainland remained obscure. This study was aimed to establish a multicenter cohort recruiting patients with CVT across 31 provinces and municipalities in China mainland. Clinical features,natural history of the diseases and current therapeutic situations will be analyzed to reveal the epidemiological features of CVT. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT. Patients will be followed-up at 1, 3, 6, 12 months from baseline to evaluate the clinical prognosis and therapeutic outcomes.
- Keywords
- Cerebral venous sinus thrombosis, Deep cerebral vein thrombosis, Cortical vein thrombosis, Cohort study, Real world evidence, Observational study, China mainland, Cerebral venous system thrombosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Death rate
A combination of death form of all causes
Measured: 1 year from baseline
Functional independence
Defined as modified Rankin score (0-5) equal to or lower than 2
Measured: 1 year from baseline
Recurrence of cerebral venous sinus thrombosis, deep cerebral venous thrombosis and cortical vein thrombosis
Diagnosed by DSA, MRV, CTV or HR-MRI
Measured: 1 year from baseline
Incidence of hemorrhagic complication
Extracranial hemorrhage (fall in hemoglobin of 2 gram/dl or more within 48 hours) or intracranial hemorrhage
Measured: 1 year from baseline
Incidence of sinus wall rupture
Measured: 1 year from baseline
Incidence of acute ischemic stroke
Measured: 1 year from baseline
Incidence of acute myocardial infarction
Measured: 1 year from baseline
Incidence of pulmonary embolism
Measured: 1 year from baseline
Incidence of deep venous thrombosis
Measured: 1 year from baseline
Secondary outcomes (2)
Incidence of epilepsy
Measured: 1 year from baseline
Incidence of allergic reaction
Measured: 1 year from baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2019
- Study start1 Jan 2019
- Primary completion31 Dec 2025
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebral Venous Sinus ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Capital Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- Beijing Municipal Science & Technology Commission
- Responsible party
- Principal investigator, Ji Xunming,MD,PhD, Capital Medical University
- Investigators
- Xunming Ji, MD, PhD, Principal investigator, Xuanwu Hospital, Beijing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03919305
- Sponsor's protocol ID
- CVT-China
- Acronym
- CCC
- Status last verified
- May 2026
- First submitted
- 3 Apr 2019
- Last updated
- 2 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No